1. Indications and Usage
\nChronic Liver Disease (CLD): Treatment of adult patients with thrombocytopenia who are scheduled for a diagnostic procedure or surgery.
\nImmune Thrombocytopenia (ITP): Treatment of adult patients with chronic primary ITP who have had an insufficient response to previous treatments (e.g., corticosteroids, immunoglobulins). It is used to increase platelet count and reduce the risk of bleeding.
\n2. Dosage and Administration
\nAdministration: Oral administration. Must be taken with food (with meals) to ensure proper absorption.
\nDosing for CLD (Pre-procedure):
\nRegimen: Once daily for 5 consecutive days. Start 10-13 days before the scheduled procedure.
\nDose: 60 mg (3 tablets) daily if baseline platelets <40\u00d710\u2079\/L; 40 mg (2 tablets) daily if baseline platelets are 40 to <50\u00d710\u2079\/L.
\nDosing for ITP (Maintenance):
\nRegimen: Start at 20 mg once daily. Adjust dose based on platelet count to maintain \u226550\u00d710\u2079\/L.
\nMax Dose: 40 mg once daily.
\n3. Mechanism of Action
\nTPO Receptor Agonist: Avatrombopag is an orally available, small-molecule agonist of the thrombopoietin (TPO) receptor.
\nPathway: It stimulates the proliferation and differentiation of bone marrow megakaryocytes, leading to increased platelet production. Unlike natural TPO, it does not compete with endogenous TPO for receptor binding .
\n4. Safety and Warnings
\nThrombosis: The most significant risk is thrombosis or thromboembolic complications (e.g., portal vein thrombosis, DVT).
\nPlatelet Count Monitoring: Dosage must be carefully managed to avoid raising platelet counts too high. For CLD patients, the goal is to raise platelets to a safe level for surgery, not to normalize them.
\n5. Adverse Reactions
\nCommon Reactions: Pyrexia (fever), abdominal pain, nausea, headache, fatigue, peripheral edema.
\nSerious Reactions: Thrombosis (Portal vein thrombosis, Deep vein thrombosis).
\n6. Drug Interactions
\nCYP2C9 and CYP3A4: Avatrombopag is metabolized by these enzymes.
\nInhibitors: Concomitant use with strong inhibitors (e.g., ketoconazole, itraconazole) may increase avatrombopag exposure and toxicity risk (monitor platelet count).
\nInducers: Concomitant use with inducers may decrease efficacy.
\nP-gp Substrate: Avatrombopag is a P-gp substrate; co-administration with inhibitors (e.g., cyclosporine, verapamil) may increase exposure.
\n7. Pharmaceutical Information
\nChemical Name: 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl}pyridin-2-yl)piperidine-4-carboxylic acid maleate
\nMolecular Formula: C29H34Cl2N6O3S2 \u00b7 C4H4O4
\nStorage: Store below 25\u00b0C. Keep container tightly closed.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u82cf\u53ef\u6b23\u00ae (Doptelet\u00ae)
\nGeneric Name: Avatrombopag Maleate
\nStrength: 20 mg per tablet, 10 tablets per blister pack
\nManufacturer: Eisai Co., Ltd. Kawashima Plant (Japan)
\nMarketing Authorization Holder: AkaRx, Inc.\uff1b\u5883\u5185\u5546\u4e1a\u5316\u8d23\u4efb\u4eba\uff1a\u4e0a\u6d77\u590d\u661f\u533b\u836f\u4ea7\u4e1a\u53d1\u5c55\u6709\u9650\u516c\u53f8
\nApproval Date in China: April 14, 2020
\nRegistration Number:\u56fd\u836f\u51c6\u5b57 H20200005
\nStorage: Store in original packaging, keep away from moisture; storage temperature 20\u2103\u201325\u2103, short-term fluctuation between 15\u2103\u201330\u2103 is acceptable; keep out of sight and reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Avatrombopag Maleate\uff08Doptelet\uff09<\/p>\n","protected":false},"featured_media":3049,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[92],"product_cat":[27],"product_tag":[],"class_list":["post-3048","product","type-product","status-publish","has-post-thumbnail","product_brand-eisai","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n